Back to search
FDAFDA · Food and drugs·Recall number Z-0359-2027

LIAISON PLEX Gram-Negative Blood Culture Assay Catalog No. 20-005-303

Published November 11, 2026 · Recall initiated: October 5, 2026

Summary

FDA records medical device Class II recall Z-0359-2027, published November 11, 2026 and initiated October 5, 2026. Recalling firm: Luminex Corporation; Status: Ongoing; Reported quantity: 30,168 test cartridges (2,514 Kits); Lot: All lots UDI-DI pending. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Instructions for Use updated to include explicit guidance that repeat testing is recommended whenever a positive family-level only result is obtained. Issue may contribute to incorrect or delayed diagnosis of bloodstream infection.

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Luminex Corporation
Distributor
US distribution nationwide. No OUS distribution.
Lot
All lots UDI-DI pending
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was LIAISON PLEX Gram-Negative Blood Culture Assay Catalog No. 20-005-303 recalled?

Yes. FDA published recall Z-0359-2027 on November 11, 2026. Reported hazard: Instructions for Use updated to include explicit guidance that repeat testing is recommended whenever a positive family-level only result is obtained. Issue may contribute to incorrect or delayed diagnosis of bloodstream infection.

What should I do if I have this product?

Voluntary: Firm initiated